Fiasp is an ultra-rapid-acting mealtime insulin that begins working within 2 to 4 minutes of subcutaneous injection. It contains the same insulin aspart molecule as Novolog but adds niacinamide and L-arginine to speed absorption. Fiasp is FDA-approved for adults and children with type 1 and type 2 diabetes and for use in insulin pumps.
How Fiasp Works
Fiasp is insulin aspart — an analog in which the amino acid proline at position B28 is replaced with aspartic acid. This change prevents insulin molecules from clumping into hexamers, so they absorb faster from the subcutaneous tissue. In Fiasp, the addition of niacinamide (vitamin B3) increases early absorption, while L-arginine stabilizes the solution and helps preserve shelf life.
The practical result is a higher and earlier insulin peak than standard aspart, with a better match to the rapid post-meal glucose rise. Fiasp still requires a separate basal insulin to cover between-meal and overnight needs. For a broader look at how mealtime insulin fits into diabetes care, see our treatment overview.
Who Uses Fiasp
Fiasp is approved for adults and children age 1 and older with type 1 or type 2 diabetes who need mealtime insulin. It is commonly chosen for:
- People with large post-meal glucose spikes despite correct pre-meal dosing with a standard rapid analog
- Children and toddlers whose meals are unpredictable (post-meal dosing is often needed)
- Insulin pump users seeking ultra-rapid action
- People with gastroparesis, where food absorption is delayed
Onset, Peak, and Duration
| Insulin | Onset | Peak | Duration |
|---|---|---|---|
| Fiasp (faster aspart) | 2 to 4 min | ~1 hr | 3 to 5 hr |
| Novolog (aspart) | 10 to 20 min | 1 to 3 hr | 3 to 5 hr |
| Lyumjev (faster lispro) | 1 to 3 min | ~1 hr | 4 to 5 hr |
| Humalog (lispro) | 10 to 15 min | 1 to 2 hr | 3 to 5 hr |
How Fiasp Is Dosed
Fiasp dosing follows the same individualized formula used for other rapid analogs:
- Insulin-to-carb ratio — often 1 unit per 10 to 15 g of carbs
- Correction factor — often 1 unit lowers glucose by 30 to 50 mg/dL
- Pre-meal target — typically 80 to 130 mg/dL
A basic mealtime dose is: (carbs ÷ carb ratio) + ((current glucose − target) ÷ correction factor). Injection timing is more flexible with Fiasp — at meal start or within 20 minutes after — but pre-meal dosing generally gives the tightest post-meal control.
Clinical Trial Results
According to the onset 1 and onset 2 pivotal trials published in Diabetes Care, adults with type 1 and type 2 diabetes who switched from conventional aspart to Fiasp saw a small additional A1C reduction of about 0.1 to 0.2 percentage points and meaningfully lower 1-hour post-meal glucose. Rates of overall hypoglycemia were similar, though rates of late post-meal hypoglycemia were modestly lower with Fiasp in some analyses.
The A1C advantage is small, but for patients who already count carbs carefully and still cannot flatten post-meal spikes, the extra speed may make a measurable difference on their A1C number.
Common Side Effects
Fiasp’s side effect profile closely resembles other rapid-acting analogs:
- Hypoglycemia (most common and most serious)
- Injection site reactions — redness, warmth, itching
- Lipohypertrophy with repeated same-site injection
- Weight gain of a few pounds
- Rare allergic reactions
Serious Warnings
Severe Hypoglycemia
Because Fiasp acts so quickly, hypoglycemia can occur sooner after dosing than with standard rapid analogs — sometimes within 30 minutes. This matters most when a meal is delayed, smaller than expected, or skipped. Always have 15 grams of fast-acting glucose within reach, and make sure family members know how to use nasal or injectable glucagon.
Hypokalemia
Like all insulins, Fiasp shifts potassium into cells and can lower serum potassium. Higher risk exists in people with kidney disease, on potassium-wasting diuretics, or with other electrolyte disturbances.
Fluid Retention with Thiazolidinediones
Combining Fiasp with pioglitazone or rosiglitazone raises the risk of fluid overload and heart failure, especially in patients with existing cardiac disease.
Drug Interactions
Beta-blockers may mask early hypoglycemia signs. Corticosteroids, atypical antipsychotics, and thiazide diuretics can raise insulin needs. Alcohol can blunt the liver’s glucose release and prolong hypoglycemia. Keep your full medication list up to date.
Hypersensitivity
Severe allergic reactions are rare but possible. Stop Fiasp and seek emergency care for a widespread rash, swelling of the face, difficulty breathing, or rapid heartbeat after injection.
Available Formulations
| Product | Strength | Delivery | Notes |
|---|---|---|---|
| Fiasp 10 mL vial | 100 units/mL | Syringe or pump | Most versatile option |
| Fiasp FlexTouch pen | 100 units/mL | Prefilled disposable pen | 1-unit increments, 1 to 80 per dose |
| Fiasp Penfill cartridge | 100 units/mL | Reusable pen cartridge | For durable pen devices |
Using Fiasp in an Insulin Pump
Fiasp is approved for continuous subcutaneous insulin infusion. Practical pointers:
- Change infusion sets every 2 to 3 days
- Some users report more frequent early site failures with Fiasp — watch for unexplained glucose rises
- Rotate sites and monitor for signs of infection
- Always keep a back-up long-acting insulin pen if the pump fails
Storage and Handling
- Unopened: refrigerate at 36 to 46 degrees Fahrenheit until expiration date
- In use: room temperature below 86 degrees for up to 28 days
- Never freeze; never expose to direct sunlight or high heat
- Discard if the solution appears cloudy, discolored, or contains particles
Fiasp vs. Lyumjev vs. Standard Rapid Analogs
Fiasp and Lyumjev are the two ultra-rapid options in the United States. Both act faster than Humalog or Novolog. Head-to-head trials have been limited, but clinical effects on post-meal glucose and A1C are broadly similar. Choice often comes down to insurance coverage, pump compatibility, and individual tolerance — some users report more injection-site stinging with Lyumjev, others with Fiasp.
When to Contact Your Care Team
- Severe hypoglycemia or loss of consciousness
- Persistent post-meal glucose above 250 mg/dL
- Vomiting, inability to hold fluids, or positive urine ketones
- New swelling, redness, or pain at injection sites
- Suspected allergic reaction
- Major schedule changes, new medications, pregnancy, or surgery
Cost and Insurance Coverage
Fiasp is covered by most commercial insurance plans and Medicare Part D, usually at the same tier as Novolog. Novo Nordisk’s patient savings card can bring the out-of-pocket cost as low as $35 per month for eligible commercial patients. Medicare Part D now caps insulin copays at $35 per month under the Inflation Reduction Act. Uninsured patients may qualify for Novo Nordisk’s patient assistance program.
Lifestyle Still Drives Outcomes
Even the fastest insulin cannot compensate for untreated insulin resistance. Regular aerobic activity, resistance training, a balanced carb plan, consistent meal timing, and sleep all lower the insulin dose needed to reach glucose targets. According to the CDC, structured lifestyle change can cut progression to type 2 diabetes by more than half in adults with prediabetes.
The Bottom Line
Fiasp is an ultra-rapid mealtime insulin that starts working within minutes, making it a practical choice for people with stubborn post-meal glucose spikes, unpredictable meals, or insulin pump use. The A1C advantage over standard Novolog is small but real, and the main risks — hypoglycemia and hypokalemia — match those of other rapid analogs. Work with your care team to decide whether Fiasp, Novolog, Humalog, or Lyumjev fits your daily routine and insurance coverage best.
